Immunohistochemical analysis on glioblastoma TMA cores showed variable cytoplasmic expression of IDO1, IDO2, and TDO2, while AhR showed variable nuclear expression in tumour cells across GBM patients. This evidence concerns the gene TDO2 and neoplasm.